MRSN
Price:
$1.35
Market Cap:
$165.61M
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name t...[Read more]
Industry
Biotechnology
IPO Date
2017-06-28
Stock Exchange
NASDAQ
Ticker
MRSN
According to Mersana Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 138.92M. This represents a change of -34.42% compared to the average of 211.83M of the last 4 quarters.
The mean historical Enterprise Value of Mersana Therapeutics, Inc. over the last ten years is 323.03M. The current 138.92M Enterprise Value has changed 4.20% with respect to the historical average. Over the past ten years (40 quarters), MRSN's Enterprise Value was at its highest in in the December 2020 quarter at 1.58B. The Enterprise Value was at its lowest in in the June 2017 quarter at -13323057.24.
Average
323.03M
Median
194.08M
Minimum
34.34M
Maximum
1.40B
Discovering the peaks and valleys of Mersana Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 620.12%
Maximum Annual Enterprise Value = 1.40B
Minimum Annual Increase = -79.91%
Minimum Annual Enterprise Value = 34.34M
Year | Enterprise Value | Change |
---|---|---|
2023 | 128.65M | -57.74% |
2022 | 304.40M | 1.72% |
2021 | 299.24M | -78.59% |
2020 | 1.40B | 620.12% |
2019 | 194.08M | 465.21% |
2018 | 34.34M | -79.91% |
2017 | 170.94M | 18.21% |
2016 | 144.61M | -38.04% |
The current Enterprise Value of Mersana Therapeutics, Inc. (MRSN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
244.10M
5-year avg
464.79M
10-year avg
323.03M
Mersana Therapeutics, Inc.’s Enterprise Value is less than Terns Pharmaceuticals, Inc. (458.36M), greater than Amylyx Pharmaceuticals, Inc. (89.50M), greater than Acumen Pharmaceuticals, Inc. (93.64M), less than Inozyme Pharma, Inc. (343.89M), greater than X4 Pharmaceuticals, Inc. (40.79M), less than Day One Biopharmaceuticals, Inc. (1.01B), greater than HOOKIPA Pharma Inc. (87.25M), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Cullinan Oncology, Inc. (930.13M), less than Relay Therapeutics, Inc. (752.45M), less than Arcus Biosciences, Inc. (1.29B), less than Kura Oncology, Inc. (1.45B), less than Protagonist Therapeutics, Inc. (2.10B), less than Merus N.V. (2.79B), less than Replimune Group, Inc. (632.78M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than Pliant Therapeutics, Inc. (762.35M), less than Syndax Pharmaceuticals, Inc. (1.52B), less than Revolution Medicines, Inc. (6.80B), less than Viridian Therapeutics, Inc. (813.50M),
Company | Enterprise Value | Market cap |
---|---|---|
458.36M | $549.60M | |
89.50M | $161.36M | |
93.64M | $133.38M | |
343.89M | $312.42M | |
40.79M | $109.78M | |
1.01B | $1.25B | |
87.25M | $159.50M | |
138.26M | $181.50M | |
930.13M | $1.04B | |
752.45M | $835.47M | |
1.29B | $1.44B | |
1.45B | $1.48B | |
2.10B | $2.44B | |
2.79B | $3.41B | |
632.78M | $708.49M | |
8.24B | $8.19B | |
762.35M | $782.51M | |
1.52B | $1.63B | |
6.80B | $6.99B | |
813.50M | $900.21M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mersana Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mersana Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Mersana Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Mersana Therapeutics, Inc. (MRSN)?
What is the 3-year average Enterprise Value for Mersana Therapeutics, Inc. (MRSN)?
What is the 5-year average Enterprise Value for Mersana Therapeutics, Inc. (MRSN)?
How does the current Enterprise Value for Mersana Therapeutics, Inc. (MRSN) compare to its historical average?